Sudarshan Pharma to Acquire 9.50% Stake in MedTherapy Biotechnology

Sudarshan Pharma Industries Ltd announced that its Board of Directors has approved the acquisition of 24,23,675.64 equity shares, representing 9.50% of the issued and outstanding share capital, in MedTherapy Biotechnology Inc. The acquisition aims to establish a presence in the U.S. market, access customer base and distribution networks, and expand into new products and services. Additionally, promoters Mr. Hemal Mehta and Mr. Sachin Mehta will individually acquire 1.50% stake each in MedTherapy Biotechnology. The transaction, to be settled in cash in US Dollars, is expected to be completed by March 31, 2027, subject to regulatory approvals, including from the Reserve Bank of India.